Bristol Myers Squibb (BMY) Return on Equity (2009 - 2026)

Bristol Myers Squibb (BMY) has 17 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Equity changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, up 2.0% from the prior year.
• Return on Equity retreated to 0.0% in Q1 2026 per BMY's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Equity topped out at 0.29% in Q2 2025 and bottomed at 0.25% in Q3 2024.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.01%.
• The widest annual swing landed in 2024, when Return on Equity dropped 23 bps; it then grew 29 bps in 2025.
• Tracing BMY's Return on Equity over 5 years: stood at 0.06% in 2022, then soared by 110 bps to 0.01% in 2023, then sank by 295 bps to 0.01% in 2024, then soared by 132 bps to 0.0% in 2025, then fell by 1 bps to 0.0% in 2026.
• Per Business Quant, the three latest BMY Return on Equity figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison